December 6th 2023
Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.
Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.
November 30th 2023
Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.
Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.
November 29th 2023
Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.
The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.
November 22nd 2023
Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.
Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.
November 15th 2023
Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.
A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).
November 14th 2023
Joshua K. Sabari, MD, discusses the ongoing phase 2 EVOKE-2 trial investigating sacituzumab govitecan-hziy in non– small cell lung cancer; emerging data on antibody-drug conjugates in the second– or first-line treatment setting; and the planned phase 3 EVOKE-03 trial of sacituzumab govitecan plus pembrolizumab as a frontline treatment.
October 10th 2023
Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.
October 3rd 2023
The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.
Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.
September 26th 2023
Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.
The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.
September 19th 2023
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.
Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.
September 12th 2023
Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.